# PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC

> **NCT07649421** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 254 (estimated)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)
- **DRUG:** Darolutamide 600 mg twice daily
- **DRUG:** Androgen Deprivation Therapy (ADT)

## Key facts

- **NCT ID:** NCT07649421
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2031-08-01
- **Final completion:** 2031-10-01
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2026-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649421, "PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*